307 related articles for article (PubMed ID: 9482108)
1. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
Paciucci R; Torà M; Díaz VM; Real FX
Oncogene; 1998 Feb; 16(5):625-33. PubMed ID: 9482108
[TBL] [Abstract][Full Text] [Related]
2. Ethanol-induced up-regulation of the urokinase receptor in cultured human endothelial cells.
Tabengwa EM; Grenett HE; Benza RL; Abou-Agag LH; Tresnak JK; Wheeler CG; Booyse FM
Alcohol Clin Exp Res; 2001 Feb; 25(2):163-70. PubMed ID: 11236828
[TBL] [Abstract][Full Text] [Related]
3. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
[TBL] [Abstract][Full Text] [Related]
4. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
De Petro G; Tavian D; Copeta A; Portolani N; Giulini SM; Barlati S
Cancer Res; 1998 May; 58(10):2234-9. PubMed ID: 9605771
[TBL] [Abstract][Full Text] [Related]
5. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
[TBL] [Abstract][Full Text] [Related]
6. Effect of heat shock on the expression of urokinase-type plasminogen activator receptor in human umbilical vein endothelial cells.
Fukao H; Hagiya Y; Ueshima S; Okada K; Takaishi T; Izaki S; Matsuo O
Thromb Haemost; 1996 Feb; 75(2):352-8. PubMed ID: 8815589
[TBL] [Abstract][Full Text] [Related]
7. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
de Vries TJ; Kitson JL; Silvers WK; Mintz B
Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
[TBL] [Abstract][Full Text] [Related]
8. Malignant transformation of human fibroblasts correlates with increased activity of receptor-bound plasminogen activator.
Jankun J; Maher VM; McCormick JJ
Cancer Res; 1991 Feb; 51(4):1221-6. PubMed ID: 1847659
[TBL] [Abstract][Full Text] [Related]
9. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
10. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Waghray A; Webber MM
Clin Cancer Res; 1995 Jul; 1(7):747-53. PubMed ID: 9816041
[TBL] [Abstract][Full Text] [Related]
11. The fibrinolytic system in neoplasia.
Bell WR
Semin Thromb Hemost; 1996; 22(6):459-78. PubMed ID: 9122711
[TBL] [Abstract][Full Text] [Related]
12. Urokinase (u-PA) is produced by collecting duct principal cells and is post-transcriptionally regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor.
Piedagnel R; Tiger Y; Lelongt B; Ronco PM
J Cell Physiol; 2006 Feb; 206(2):394-401. PubMed ID: 16155905
[TBL] [Abstract][Full Text] [Related]
13. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
Robert C; Bolon I; Gazzeri S; Veyrenc S; Brambilla C; Brambilla E
Clin Cancer Res; 1999 Aug; 5(8):2094-102. PubMed ID: 10473092
[TBL] [Abstract][Full Text] [Related]
14. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis.
Esposito I; Penzel R; Chaib-Harrireche M; Barcena U; Bergmann F; Riedl S; Kayed H; Giese N; Kleeff J; Friess H; Schirmacher P
J Pathol; 2006 Apr; 208(5):673-85. PubMed ID: 16450333
[TBL] [Abstract][Full Text] [Related]
15. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibition of vascular smooth muscle cells derived from urokinase receptor (u-PAR)-deficient mice in the presence of carcinoma cells.
Ueshima S; Fukao H; Okada K; Matsuo O
Thromb Res; 2004; 113(1):41-9. PubMed ID: 15081564
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor.
Fibbi G; Caldini R; Chevanne M; Pucci M; Schiavone N; Morbidelli L; Parenti A; Granger HJ; Del Rosso M; Ziche M
Lab Invest; 1998 Sep; 78(9):1109-19. PubMed ID: 9759655
[TBL] [Abstract][Full Text] [Related]
19. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
Landau BJ; Kwaan HC; Verrusio EN; Brem SS
Cancer Res; 1994 Feb; 54(4):1105-8. PubMed ID: 8313368
[TBL] [Abstract][Full Text] [Related]
20. Stable expression of antisense urokinase mRNA inhibits the proliferation and invasion of human hepatocellular carcinoma cells.
Tavian D; Salvi A; De Petro G; Barlati S
Cancer Gene Ther; 2003 Feb; 10(2):112-20. PubMed ID: 12536199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
